On Saturday, December 1, 2018, the University Hospital of Zurich (USZ), Switzerland, led by the ECMO team under the direction of Max Halbe, Chief Perfusionist, hosted its first interdisciplinary symposium, Mechanical Circulation Support (MCS,) in the hospital facilities. More than 80 participants from the medical field, predominantly medical doctors and perfusionists, attended the inaugural event.
Well renowned speakers from Switzerland and Germany from a cross-section of disciplines such as anesthesiology, cardiac surgery, intensive care medicine, cardiology and perfusion presented the historical background as well as the current state in mechanical circulation support including such technical aspects as cannulation and venting. The presentations clearly demonstrated that there is a current trend in the increased use of techniques such as extracorporeal membrane oxygenation (ECMO) / extracorporeal life support (ECLS) and other forms of mechanical circulation support.
The day began with introductory talks by Professors Ruschitzka and Wilhelm that stressed the importance for medical practitioners to bear in mind that when treating patients requiring mechanical circulatory support, often, if not in all instances, systemic hyperinflammation is present too, and plays a crucial role that can affect the further clinical course of the patient and potentially impact on the final outcome. Appropriate treatment strategies should therefore not only focus on the circulation support itself, but also on the hyperinflammatory situation present.
The afternoon sessions included practical workshops on cardiogenic shock, septic shock and Impella use, and offered insights into the technical set up of mechanical circulation support which included the integration of the CytoSorb adsorber into an ECLS circuit.
All in all, it was a day filled with informative and engaging presentations on this increasingly effective and promising therapy outlining the pathophysiologic rationale for its use and, equally as important, guidance was also provided for the practical application.
Next years’ event has already been announced for November 30, 2019 and we look forward to rejoining our colleagues and learning how the use of these therapies evolves over the coming months.
During your daily work at the patients’ bedside or when doing research in preparation for a lecture or a publication, you would love to gather a broad overview of the available literature surrounding CytoSorb therapy.
The core of our new Literature Database is its structured keyword search tool, which provides a sophisticated search engine, adapted to your current issue:
The search results contain short summaries or released full text. Follow the link to source (for e.g. PubMed.gov) or download released PDF’s (i.e. Case of the week).
We are certain that this easy to use tool with its extensive overview of CytoSorb literature will be of major benefit for you. As always our goal is to provide you with useful tools, in order to give you the best possible support.
For quick and easy access to the CytoSorb Literature Database, bookmark the following link: http://literature.cytosorb.com
Discover the new CytoSorb Literature Database now – we look forward to hearing your opinion!
The Roger-Bone-Prize for clinical sepsis research, selected by the German Sepsis Society, is awarded every year to young scientists from German speaking countries. CytoSorbents Europe is happy to once again support this research prize. We congratulate Dr. Christian Scheer from the Anesthesiology Clinic, Greifswald University hospital (Germany), who received the Roger-Bone-Prize 2017 during the 2017 Sepsis Update Congress in Weimar for his publication „Quality improvement initiative for severe sepsis and septic shock reduces 90-day mortality: A 7.5-year observational study“ (Crit Care Med 2017; 45(2):241-252).
The day before the start of the 37th ISICEM, the 4th International Users Meeting brought together 120 CytoSorb users and other interested parties from a total of 22 countries. The international faculty shared an update on the latest scientific findings, recent study results and case series in different patient groups, followed by a podium discussion.
>> read more
Continued Flow of Data Correlating Positive Clinical Improvements with CytoSorb® Usage
BRUSSELS, BELGIUM, March 16, 2016 – CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® blood filtration technology to reduce deadly uncontrolled inflammation in critically-ill and cardiac surgery patients around the world, announced the conclusion of its successful 3rd International CytoSorb Users Meeting in Brussels, Belgium. Held one day ahead of the International Symposium of Intensive Care and Emergency Medicine (ISICEM), one of the largest international critical care conferences, the Users Meeting brought together 107 members of the CytoSorb® community from a total of 23 countries, to share data from many new pre-clinical and clinical studies. To date, more than 10,000 CytoSorb® treatments have been performed in thousands of patients.
Some of the most important findings include:
Dr. Phillip Chan, Chief Executive Officer, stated,
“We are pleased to report this initial summary of the 3rd International CytoSorb® Users Meeting. The purpose of these meetings is to disseminate the lessons learned from experienced users so that we can ensure uniformity of treatment and that all users worldwide benefit from the latest information. Although there is always more to learn, we are pleased to see that when CytoSorb® is used in the right way, users continue to experience positive results with the treatment. As we have done in the past, a more detailed report of this meeting will be published in a proceedings booklet that will be available at our CytoSorb website.”